Literature DB >> 3759958

Prothrombin fragment 1 X 2 X 3, a major product of prothrombin activation in human plasma.

M J Rabiet, A Blashill, B Furie, B C Furie.   

Abstract

The conversion of the blood coagulation zymogen prothrombin to thrombin is associated with the production of several cleavage intermediates and products. In contrast to earlier studies of prothrombin cleavage in chemically defined systems, the current investigation examines the fragmentation of human prothrombin in normal plasma. Radiolabeled prothrombin was added to platelet-poor relipidated normal human plasma, and clotting was initiated with the addition of Ca(II) and kaolin. Analysis of the radiolabeled prothrombin cleavage products by polyacrylamide gel electrophoresis in the presence of dodecyl sulfate and beta-mercaptoethanol identified a heretofore unobserved product of prothrombin activation with an apparent molecular weight of 45,000. This product was identified as fragment 1 X 2 X 3, the NH2-terminal 286 amino acids of prothrombin. The product was isolated from a prothrombin digest by immunoaffinity chromatography using anti-prothrombin:Ca(II) antibodies and by preparative gel electrophoresis. Its amino-terminal sequence is identical to that of prothrombin. Digestion of this product with either Factor Xa or thrombin yields, at a minimum, fragment 1 X 2 and fragment 1. Amino-terminal sequence analysis of the products obtained by digestion with Factor Xa of the unknown activation product indicated 3 amino acid residues at each cycle consistent with the presence of fragment 1, fragment 2, and fragment 3. To unambiguously identify the COOH-terminal amino acid sequence of the product, its factor Xa digestion products were separated by reverse-phase high performance liquid chromatography. Edman degradation of one peptide revealed the complete sequence of fragment 3. On this basis, we identify the Mr 45,000 polypeptide as fragment 1 X 2 X 3 and indicate that it is a prominent product of prothrombin conversion to thrombin when activation occurs in plasma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759958

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Identification of disulfide bonds in protein proteolytic degradation products using de novo-protein unique sequence tags approach.

Authors:  Yufeng Shen; Nikola Tolić; Samuel O Purvine; Richard D Smith
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

2.  Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.

Authors:  Caroline Gravastrand; Shamal Hamad; Hilde Fure; Bjørg Steinkjer; Liv Ryan; Josè Oberholzer; John D Lambris; Igor Lacík; Tom Eirik Mollnes; Terje Espevik; Ole-Lars Brekke; Anne Mari Rokstad
Journal:  Acta Biomater       Date:  2017-05-30       Impact factor: 8.947

Review 3.  Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.

Authors:  A Ceriello
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

4.  A Genus-Wide Bioactivity Analysis of Daboia (Viperinae: Viperidae) Viper Venoms Reveals Widespread Variation in Haemotoxic Properties.

Authors:  Bianca Op den Brouw; Francisco C P Coimbra; Nicholas R Casewell; Syed Abid Ali; Freek J Vonk; Bryan G Fry
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.